advertisement
PURPOSE: Omentin, a member of the adipocytokines family, is derived from adipose tissue and a lower level of serum omentin is considered as a metabolic risk factor. The aim of the present study is to evaluate the serum levels of omentin in patients with pseudoexfoliation syndrome (PES). MATERIALS AND METHODS: Patients without any systemic or ocular disease other than PES were included in the study. Age-matched and sex-matched healthy volunteers without PES were accepted as a control group. After detailed ophthalmologic examination, blood samples were obtained from a forearm vein. Serum levels of omentin were determined by the method of enzyme-linked immunosorbent assay. RESULTS: The mean age of the PES group (12 females, 12 males, n=24) was 75.2±8.4 years, and the control group (10 females, 10 males, n=20) was 75±6.7 years. There was no difference between the groups in terms of age (P=0.93) and sex (P=0.9). The mean serum levels of omentin in the PES group were 801.5±317.1 ng/mL and in the control group were 1150.1±584.1 ng/mL. The mean serum omentin levels were significantly lower in patients with PES (P=0.016). CONCLUSION: Lower levels of serum omentin in patients with PES compared with healthy subjects may support the theory of systemic nature of the disease.
*Ophthalmology Clinic, Izzet Baysal State Hospital Departments of †Medical Biochemistry ¶Ophthalmology, Abant Izzet Baysal University Medical School, Bolu §Department of Ophthalmology, Duzce University Medical School, Duzce ‡Department of Ophthalmology, Pamukkale University School of Medicine, Denizli ∥Department of Ophthalmology, Hacettepe University Medical School, Ankara.
Full article9.4.4.1 Exfoliation syndrome (Part of: 9 Clinical forms of glaucomas > 9.4 Glaucomas associated with other ocular and systemic disorders > 9.4.4 Glaucomas associated with disorders of the lens)
3.7 Biochemistry (Part of: 3 Laboratory methods)
9.4.15 Glaucoma in relation to systemic disease (Part of: 9 Clinical forms of glaucomas > 9.4 Glaucomas associated with other ocular and systemic disorders)